FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118323113> ?p ?o ?g. }

• W3118323113 abstract "Glaucoma, the most perilous disease leading to blindness is a result of optical neuropathy. Accumulation of aqueous humor in the posterior chamber due to a large difference in the rate of formation and its drainage in the anterior chamber causes an increase in intraocular pressure (IOP) leading to damage of nerve cells. A literature survey has revealed that inhibition of the Rho guanosine triphosphatases (rho GTPase) pathway by specific inhibitors leads to the relaxation of contractile cells involved in the aqueous outflow pathway. Relaxation of the strained contractile cells results in increased outflow thereby releasing IOP. In the present study molecular docking has been used to screen twenty seven bioactive (17 natural compounds and 10 conventional drugs) compounds that may play a significant role in relaxing contractile cells by inhibiting rho-GTPase protein. Docking results showed that among all-natural bioactive compounds Cyanidin and Delphinidine have a good binding affinity (- 8.4 kcal/mol) than the top screened conventional drug molecule Mitomycin, (- 6.3 kcal/mol) when docked with rho-GTPase protein. Cyanidin and Delphinidin belong to anthocyanidin, a glycoside form of anthocyanins from Vaccinium myrtillus L. and Punica granatum. The resembling potential of Cyanidin and Delphinidin concerning the drug Mitomycin was confirmed through simulation analysis. Molecular dynamics study (MDS) for 100 ns, showed that the rho GTPase-Delphinidine complex structure was energetically more stable than rho GTPase-Cyaniding complex in comparison to rho GTPase-Mitomycin complex. The comparative study of both the selected hits (Cyanidin and Delphinidin) was assessed by RMSD, RMSF, Rg, SASA, H-bond, PCA MM/PBSA analysis. The analysis revealed that Delphinidine is more potent to inhibit the rho GTPase as compare to Cyaniding and available conventional drugs in terms of stability and binding free energy. Based on the results, these molecules have good pharmacokinetic and pharmacodynamics properties and will prove to be a promising lead compound as a future drug for Glaucoma." @default.
• W3118323113 created "2021-01-18" @default.
• W3118323113 creator A5032506165 @default.
• W3118323113 creator A5054553587 @default.
• W3118323113 creator A5066766531 @default.
• W3118323113 creator A5083571688 @default.
• W3118323113 creator A5089226723 @default.
• W3118323113 date "2021-01-03" @default.
• W3118323113 modified "2023-10-16" @default.
• W3118323113 title "Chemo-informatics guided study of natural inhibitors targeting rho GTPase: a lead for treatment of glaucoma" @default.
• W3118323113 cites W1485052207 @default.
• W3118323113 cites W1557248051 @default.
• W3118323113 cites W1969824248 @default.
• W3118323113 cites W1996005642 @default.
• W3118323113 cites W1998749968 @default.
• W3118323113 cites W2021933371 @default.
• W3118323113 cites W2022805799 @default.
• W3118323113 cites W2030594278 @default.
• W3118323113 cites W2033495141 @default.
• W3118323113 cites W2046204854 @default.
• W3118323113 cites W2057266151 @default.
• W3118323113 cites W2059158315 @default.
• W3118323113 cites W2069738597 @default.
• W3118323113 cites W2077080652 @default.
• W3118323113 cites W2079743301 @default.
• W3118323113 cites W2081577607 @default.
• W3118323113 cites W2087083517 @default.
• W3118323113 cites W2138742704 @default.
• W3118323113 cites W2145192598 @default.
• W3118323113 cites W2156878508 @default.
• W3118323113 cites W2160605010 @default.
• W3118323113 cites W2170177550 @default.
• W3118323113 cites W2171365654 @default.
• W3118323113 cites W2188225742 @default.
• W3118323113 cites W2238003108 @default.
• W3118323113 cites W2398842730 @default.
• W3118323113 cites W2405379955 @default.
• W3118323113 cites W2771163297 @default.
• W3118323113 cites W4248107770 @default.
• W3118323113 doi "https://doi.org/10.1007/s40203-020-00061-y" @default.
• W3118323113 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7778655" @default.
• W3118323113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33442531" @default.
• W3118323113 hasPublicationYear "2021" @default.
• W3118323113 type Work @default.
• W3118323113 sameAs 3118323113 @default.
• W3118323113 citedByCount "7" @default.
• W3118323113 countsByYear W31183231132022 @default.
• W3118323113 countsByYear W31183231132023 @default.
• W3118323113 crossrefType "journal-article" @default.
• W3118323113 hasAuthorship W3118323113A5032506165 @default.
• W3118323113 hasAuthorship W3118323113A5054553587 @default.
• W3118323113 hasAuthorship W3118323113A5066766531 @default.
• W3118323113 hasAuthorship W3118323113A5083571688 @default.
• W3118323113 hasAuthorship W3118323113A5089226723 @default.
• W3118323113 hasBestOaLocation W31183231132 @default.
• W3118323113 hasConcept C12554922 @default.
• W3118323113 hasConcept C159110408 @default.
• W3118323113 hasConcept C185592680 @default.
• W3118323113 hasConcept C201800478 @default.
• W3118323113 hasConcept C207332259 @default.
• W3118323113 hasConcept C2777667348 @default.
• W3118323113 hasConcept C2778945092 @default.
• W3118323113 hasConcept C2781021748 @default.
• W3118323113 hasConcept C31903555 @default.
• W3118323113 hasConcept C41685203 @default.
• W3118323113 hasConcept C55493867 @default.
• W3118323113 hasConcept C62478195 @default.
• W3118323113 hasConcept C71924100 @default.
• W3118323113 hasConcept C86803240 @default.
• W3118323113 hasConcept C98274493 @default.
• W3118323113 hasConceptScore W3118323113C12554922 @default.
• W3118323113 hasConceptScore W3118323113C159110408 @default.
• W3118323113 hasConceptScore W3118323113C185592680 @default.
• W3118323113 hasConceptScore W3118323113C201800478 @default.
• W3118323113 hasConceptScore W3118323113C207332259 @default.
• W3118323113 hasConceptScore W3118323113C2777667348 @default.
• W3118323113 hasConceptScore W3118323113C2778945092 @default.
• W3118323113 hasConceptScore W3118323113C2781021748 @default.
• W3118323113 hasConceptScore W3118323113C31903555 @default.
• W3118323113 hasConceptScore W3118323113C41685203 @default.
• W3118323113 hasConceptScore W3118323113C55493867 @default.
• W3118323113 hasConceptScore W3118323113C62478195 @default.
• W3118323113 hasConceptScore W3118323113C71924100 @default.
• W3118323113 hasConceptScore W3118323113C86803240 @default.
• W3118323113 hasConceptScore W3118323113C98274493 @default.
• W3118323113 hasIssue "1" @default.
• W3118323113 hasLocation W31183231131 @default.
• W3118323113 hasLocation W31183231132 @default.
• W3118323113 hasLocation W31183231133 @default.
• W3118323113 hasOpenAccess W3118323113 @default.
• W3118323113 hasPrimaryLocation W31183231131 @default.
• W3118323113 hasRelatedWork W2005122266 @default.
• W3118323113 hasRelatedWork W2040095383 @default.
• W3118323113 hasRelatedWork W2061661430 @default.
• W3118323113 hasRelatedWork W2067667471 @default.
• W3118323113 hasRelatedWork W2070490092 @default.
• W3118323113 hasRelatedWork W2324796485 @default.
• W3118323113 hasRelatedWork W2907912795 @default.
• W3118323113 hasRelatedWork W3142579904 @default.
• W3118323113 hasRelatedWork W4308891831 @default.

• next